What are biomarkers?

Current Opinion in HIV and AIDS

Volumn 5, Issue 6, 2010, Pages 463-466

  Strimbu, Kyle ^a   Tavel, Jorge A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Biomarkers; clinical endpoints; surrogate endpoints

Indexed keywords

BIOLOGICAL MARKER;

CLINICAL ENDPOINT; CLINICAL RESEARCH; DISEASE MARKER; FOOD AND DRUG ADMINISTRATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SURROGATE ENDPOINT; WORLD HEALTH ORGANIZATION;

BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; DIAGNOSIS; HUMANS; REPRODUCIBILITY OF RESULTS;

EID: 77958586852     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32833ed177     Document Type: Review

References (12)

1. Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69:89-95.
2. WHO International Programme on Chemical Safety. Biomarkers in risk assessment: validity and validation; 2001. http://www.inchem.org/docu-ments/ehc/ ehc/ehc222.htm.
3. WHO International Programme on Chemical Safety. Biomarkers and risk assessment: concepts and principles; 1993. http://www.inchem.org/docu-ments/ehc/ ehc/ehc155.htm.
4. Fleming TR, DeMets DL Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125:605-613.
5. D'Agostino RB Jr. Debate: the slippery slope of surrogate outcomes. Curr Control Trials Cardiovasc Med 2000; 1:76-78.
6. DeGruttola D, Fleming TR, Lin DY, Coombs R. Perspective: Validating surrogate markers: Are we being naïve? J Infect Dis 1997; 127:237-246.
7. Mitka M. Controversies surround heart drug study: questions about Vytorin and trial sponsors' conduct. JAMA 2008; 299:885-887.
8. Food and Drug Administration Modernization Act of 1997, 21CFR314 http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmetic ActFDCAct/SignificantAmendmentstotheFDCAct/FDAMA/FullTextofFDAMAlaw/default.htm.
9. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N Engl J Med 1991; 324:509-516.
10. Ellenberg SS, Hamilton JM. Surrogate endpoints in clinical trials: cancer. Stat Med 1989; 8:405-413.
11. Wittes J, Lakatos E, PRobstfield J. Surrogate endpoints in clinical trials: cardiovascular diseases. Stat Med 1989; 8:415-425.
12. Food and Drug Administration. Innovation and stagnation: challenges and opportunity on the critical path to new medical products (white paper); 2004, updated 2010. http://www.fda.gov/ScienceResearch/SpecialTopics/Criti- calPathInitiative/ucm204289.htm.